ADAM CLAY: Open Payments
NPI 1265881007 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,304 in 99 payments from 19 companies in 2025. Trend: 2023 $703 · 2024 $1,175 · 2025 $2,304
Food & beverage: $2,255Education: $50
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 24 | $369 |
| Philips North America LLC | 12 | $240 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $233 |
| Alnylam Pharmaceuticals Inc. | 5 | $188 |
| E.R. Squibb & Sons, L.L.C. | 6 | $176 |
| Merck Sharp & Dohme LLC | 8 | $173 |
| Amgen Inc. | 6 | $148 |
| AstraZeneca Pharmaceuticals LP | 3 | $126 |
| Abbott Laboratories | 2 | $116 |
| Inspire Medical Systems, Inc. | 3 | $109 |
Products named: Kerendia, Ambulatory Monitoring & Diagnostics Undivided, VYNDAQEL, AMVUTTRA, ELIQUIS, CAMZYOS, VERQUVO, REPATHA.
Industry payments across MS — which companies pay providers there.
